SHILPA MEDICARE LIMITED (SHILPAMED): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹933.85 latest close · +53.4% over the last 90 sessions

₹933.85 month-end · +173.5% over 12 months

₹933.85 month-end · +411.1% over 3 years

₹933.85 month-end · +391.4% since Jan '19

52-week range ₹259.50 to ₹1095.00 · 1-year volatility 43.0%

Was the rally earned?

1 year5 years

+174%share price, 1 yearEarnings-driven

Mostly yes.

Per-share earnings added 170 points to the rise, while the multiple moved less (P/E 60.1x to 61.4x).
The share count barely moved.

Net profit growth+168 ptsNet profit rose about 165%, which lifts the price.

P/E change+4 ptsThe P/E rose from 60.1x to 61.4x, which lifts the price.

Share count change+2 ptsShare count was little changed. More shares would count against the price.

+244%share price, 5 yearsEarnings and multiple

Both mattered.

Per-share earnings added 102 points and the multiple added 141 points (P/E 30.0x to 61.4x).
The share count rose 21%.

Net profit growth+140 ptsNet profit rose about 104%, which lifts the price.

P/E change+141 ptsThe P/E rose from 30.0x to 61.4x, which lifts the price.

Share count change-38 ptsShare count rose 21%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-65.7%recovered 2024-07

1-year volatility43.0%annualised

Beta vs sector index1.463-year daily, correlation 0.47

Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-65.7% (2020-08 peak to 2023-03 low, recovered 2024-07)

-52.5% (2020-02 peak to 2020-03 low, recovered 2020-06)

-49.2% (2019-04 peak to 2019-08 low, recovered 2020-02)

Most recent volume spikes

2026-08-10: 7.8x the 50-day median, price +6.3% that day

2026-08-07: 7.7x the 50-day median, price +2.8% that day

2026-08-06: 25.3x the 50-day median, price +2.4% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

61.4xP/E todayWithin its usual range

Against its own history75th percentile

CheapestMedian 34.2xDearest

Usual range 22.0x to 110.3x since 2019-01.

Against Health Technology61.4x vs 37.0x

This company

61.4x

Sector median

37.0x

66% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE36th▲ 12 pts vs a year ago
Op. margin87thflat vs a year ago
Revenue growth79th▲ 19 pts vs a year ago
EPS growth94thflat vs a year ago
Debt/equity ↓47th▲ 3 pts vs a year ago
Cash cycle ↓16th▲ 9 pts vs a year ago
P/E ↓23rdflat vs a year ago
12M momentum97th▲ 57 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~48%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 239.0x, a holder earning 12%/yr needs earnings to grow about 47.5%/yr for 10 years, then trade at 15x.

Delivered−1.3%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg

Gap+48.8 ptsimplied minus delivered

Rank13thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	49.5%	50.8%	52.2%
15x	46.2%	47.5%	48.9%
20x	42.1%	43.4%	44.7%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 47.5%/yr

Looking back

Jan 2020Price implied 15%/yr; EPS has since grown 9%/yr (7.0 yrs)
Jan 2021Price implied 16%/yr; EPS has since grown 5%/yr (6.0 yrs)
Jan 2022Price implied 21%/yr; EPS has since grown 7%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹933.85
P/E: 61.4x
ROCE: 11.0%
Market Cap: ₹18257 cr
Revenue (TTM): ₹1683 cr
P/S: 10.8x
P/B: 7.0x
ROE: 11.5%
Operating Margin: 29.0%
Debt / Equity: 0.3x
Promoter Holding: 40.1%
12M Momentum: 173.5%

52-week range

₹259.50₹1095.00

81% of the way from its 52-week low to its high

Price risk

1Y volatility

43.0%

Beta vs sector

1-year daily

1.47

Balance sheet & cash

Interest cover

operating profit ÷ interest

7.5x

Cash from profit, 3Y

operating cash flow ÷ net profit

1.73x

Share count, 1Y

unchanged

Are profits backed by cash?

6 of 7checks within range1 beyond a threshold

Other income reliance13%Within range

Other income as a share of pre-tax profit (trailing twelve months): 12.5%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate18%Within range

Median quarterly effective tax rate over about 2.5 years: 18.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.73xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.73x (cash from operations ₹611 cr, net profit ₹353 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-2 daysWithin range

Debtor days are below the median of the previous three fiscal years by 2 days (123 vs 125). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress55% of fixed assetsWithin range

Capital work-in-progress is 55% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-43 days / 2 yrsWithin range

Days payable changed by -43 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, promoters trimmed 9.9 pts; DIIs added 8.0 pts; FIIs added 2.9 pts.
The number of shareholders rose from 43,630 to 60,926 (+40%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters50.0%40.1%-9.9 pts

FIIs8.5%11.4%+2.9 pts

DIIs0.1%8.1%+8.0 pts

Public and others41.4%40.4%-1.0 pts

Number of shareholders

60,926shareholders+40% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−6.4%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like SHILPA MEDICARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −29% to +18% vs the market, against −4% for all non-financial companies in the same months.
The gap against the base rate (−2.9%, 80% range −12.5% to +5.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−6.4%

All companies' median

−3.5%

Beat the market

44% vs 46%

50 past situations · 50 companies · 38 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
LAURUSLABS Health Technology	Nov 2020	66x	14%	+352%	−6%	+14%
SHAILY Process Industries	Apr 2025	84x	14%	+141%	−21%	+55%
ANANTRAJ Consumer Durables	Sep 2024	78x	9%	+221%	−5%	+7%
CARTRADE Technology Services	Jun 2025	60x	8%	+118%	−6%	+58%
ACUTAAS Process Industries	Feb 2025	91x	16%	+95%	−17%	+69%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GRANULES Health Technology	Sep 2020	29x	17%	+267%	−4%	−49%
TRIDENT Process Industries	Nov 2021	85x	10%	+558%	−10%	−38%
FLUOROCHEM Process Industries	Jun 2022	39x	20%	+139%	−12%	−12%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, interest cover and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SHILPA MEDICARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

SANSERA ENGINEERINGSANSERA

Producer Manufacturing

67%similar

revenue growthvolatility

YATHARTH HOSPITAL TRAUMAYATHARTH

Health Services

60%similar

P/Erevenue

AZAD ENGINEERINGAZAD

Producer Manufacturing

58%similar

market capROCE

RATEGAIN TRAVEL TECHNOLOGIESRATEGAIN

Technology Services

56%similar

volatilityrevenue

ASTRA MICROWAVE PRODUCTSASTRAMICRO

Electronic Technology

55%similar

market capdebt/equity

WOCKHARDTWOCKPHARMA

Health Technology

62%similar

P/Emarket cap

ONESOURCE SPECIALTY PHARMAONESOURCE

Health Technology

61%similar

market caprevenue

POLY MEDICUREPOLYMED

Health Technology

58%similar

volatilitymarket cap

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Nov '23

2026
AugPriceVolume reached 25.3x its 50-day median on 2026-08-06; price +2.4% that day.
JunPeer rankMoved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
JunDividendDividend payout cut from 12% to 5% of profit.
MayPriceRegained the 2025-06 peak, 4 months after the low.
MayPriceVolume reached 12.0x its 50-day median on 2026-05-22; price +3.3% that day.
MarPromoterPromoter holding fell 4.1 pts to 40.1% (largest drop since 2024-09).
MarPriceVolume reached 48.6x its 50-day median on 2026-03-24; price +8.2% that day.
JanPriceFell 46% from the Jun 2025 peak to the Jan 2026 low.

Show 22 earlier events

2026
JanDebtDebt / equity halved over 12 months to 0.25x.
2025
NovPriceVolume reached 6.8x its 50-day median on 2025-11-13; price -2.4% that day.
SepPriceVolume reached 6.8x its 50-day median on 2025-09-23; price +0.8% that day.
JunResultsYear-on-year EPS growth turned positive.
JunPriceRegained the 2024-11 peak, 3 months after the low.
JunPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
JunDebtDebt / equity halved over 12 months to 0.25x.
JunDividendStarted paying a dividend (payout 12% of profit).
JunSharesShare count is up 11.1% over 12 months.
MayPriceVolume reached 26.9x its 50-day median on 2025-05-26; price +13.6% that day.
MarPriceFell 36% from the Nov 2024 peak to the Mar 2025 low.
MarPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
MarPriceVolume reached 12.2x its 50-day median on 2025-03-21; price +3.8% that day.
2024
DecPriceVolume reached 6.9x its 50-day median on 2024-12-11; price +5.1% that day.
SepPromoterPromoter holding fell 5.6 pts to 44.4%.
SepInstitutionsFII + DII holding rose 9.4 pts over 1 quarter to 16.7%.
JulPriceRegained the 2020-08 peak, 16 months after the low.
JulPriceVolume reached 14.7x its 50-day median on 2024-07-05; price +13.9% that day.
JunResultsEPS (TTM) turned positive.
JunValuationP/E crossed above the 90th percentile of its own history to date (155.6x).
FebPriceVolume reached 17.5x its 50-day median on 2024-02-19; price +9.3% that day.
2023
NovPriceVolume reached 9.2x its 50-day median on 2023-11-10; price +4.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	61.4x	₹1683 cr	11.5%	11.0%	0.3x
2026-10	62.9x	₹1683 cr	11.5%	11.0%	0.3x
2026-09	68.9x	₹1683 cr	11.5%	11.0%	0.3x
2026-08	76.3x	₹1538 cr	9.4%	11.0%	0.3x
2026-07	49.1x	₹1538 cr	9.4%	11.0%	0.3x
2026-06	48.1x	₹1538 cr	9.4%	11.0%	0.3x
2026-05	65.1x	₹1432 cr	6.4%	8.0%	0.2x
2026-04	53.0x	₹1432 cr	6.4%	8.0%	0.2x
2026-03	45.5x	₹1432 cr	6.4%	8.0%	0.2x
2026-02	48.0x	₹1341 cr	5.8%	8.0%	0.2x
2026-01	41.2x	₹1341 cr	5.8%	8.0%	0.2x
2025-12	45.8x	₹1341 cr	5.8%	8.0%	0.2x
2025-11	60.1x	₹1315 cr	4.7%	8.0%	0.2x
2025-10	62.1x	₹1315 cr	4.7%	8.0%	0.2x
2025-09	66.3x	₹1315 cr	4.7%	8.0%	0.2x
2025-08	105.8x	₹1287 cr	3.3%	8.0%	0.2x
2025-07	111.0x	₹1287 cr	3.3%	8.0%	0.2x
2025-06	111.3x	₹1287 cr	3.3%	8.0%	0.2x
2025-05	96.5x	₹1248 cr	4.9%	5.0%	0.5x
2025-04	69.3x	₹1248 cr	4.9%	5.0%	0.5x
2025-03	71.0x	₹1248 cr	4.9%	5.0%	0.5x
2025-02	92.2x	₹1216 cr	3.4%	5.0%	0.5x
2025-01	107.2x	₹1216 cr	3.4%	5.0%	0.5x
2024-12	123.2x	₹1216 cr	3.4%	5.0%	0.5x
2024-11	181.0x	₹1185 cr	2.5%	5.0%	0.5x
2024-10	170.2x	₹1185 cr	2.5%	5.0%	0.5x
2024-09	164.0x	₹1185 cr	2.5%	5.0%	0.5x
2024-08	209.7x	₹1152 cr	1.8%	5.0%	0.5x
2024-07	186.1x	₹1152 cr	1.8%	5.0%	0.5x
2024-06	155.6x	₹1152 cr	1.8%	5.0%	0.5x
2024-05	—	₹1046 cr	-1.7%	1.0%	0.4x
2024-04	—	₹1046 cr	-1.7%	1.0%	0.4x
2024-03	—	₹1046 cr	-1.7%	1.0%	0.4x
2024-02	—	₹1046 cr	-1.7%	1.0%	0.4x
2024-01	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-12	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-11	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-10	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-09	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-08	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-07	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-06	—	₹1046 cr	-1.7%	1.0%	0.4x
2023-05	34.2x	₹1141 cr	3.3%	6.0%	0.4x
2023-04	36.8x	₹1141 cr	3.3%	6.0%	0.4x
2023-03	32.8x	₹1141 cr	3.3%	6.0%	0.4x
2023-02	36.9x	₹1141 cr	3.3%	6.0%	0.4x
2023-01	35.2x	₹1141 cr	3.3%	6.0%	0.4x
2022-12	39.9x	₹1141 cr	3.3%	6.0%	0.4x
2022-11	40.3x	₹1141 cr	3.3%	6.0%	0.4x
2022-10	45.1x	₹1141 cr	3.3%	6.0%	0.4x
2022-09	55.4x	₹1141 cr	3.3%	6.0%	0.4x
2022-08	56.5x	₹1141 cr	3.3%	6.0%	0.4x
2022-07	59.0x	₹1141 cr	3.3%	6.0%	0.4x
2022-06	55.8x	₹1141 cr	3.3%	6.0%	0.4x
2022-05	24.0x	₹899 cr	9.9%	8.0%	0.6x
2022-04	25.2x	₹899 cr	9.9%	8.0%	0.6x
2022-03	22.0x	₹899 cr	9.9%	8.0%	0.6x
2022-02	22.4x	₹899 cr	9.9%	8.0%	0.6x
2022-01	28.0x	₹899 cr	9.9%	8.0%	0.6x
2021-12	29.5x	₹899 cr	9.9%	8.0%	0.6x
2021-11	30.0x	₹899 cr	9.9%	8.0%	0.6x
2021-10	32.2x	₹899 cr	9.9%	8.0%	0.6x
2021-09	30.7x	₹899 cr	9.9%	8.0%	0.6x
2021-08	31.8x	₹899 cr	9.9%	8.0%	0.6x
2021-07	34.8x	₹899 cr	9.9%	8.0%	0.6x
2021-06	29.8x	₹899 cr	9.9%	8.0%	0.6x
2021-05	27.1x	₹908 cr	11.7%	12.0%	0.3x
2021-04	22.3x	₹908 cr	11.7%	12.0%	0.3x
2021-03	17.4x	₹908 cr	11.7%	12.0%	0.3x
2021-02	19.3x	₹908 cr	11.7%	12.0%	0.3x
2021-01	22.1x	₹908 cr	11.7%	12.0%	0.3x
2020-12	23.5x	₹908 cr	11.7%	12.0%	0.3x
2020-11	24.6x	₹908 cr	11.7%	12.0%	0.3x
2020-10	23.4x	₹908 cr	11.7%	12.0%	0.3x
2020-09	29.2x	₹908 cr	11.7%	12.0%	0.3x
2020-08	27.5x	₹908 cr	11.7%	12.0%	0.3x
2020-07	28.7x	₹908 cr	11.7%	12.0%	0.3x
2020-06	24.8x	₹908 cr	11.7%	12.0%	0.3x
2020-05	28.6x	₹733 cr	9.2%	9.0%	0.2x
2020-04	26.5x	₹733 cr	9.2%	9.0%	0.2x
2020-03	17.8x	₹733 cr	9.2%	9.0%	0.2x
2020-02	33.2x	₹733 cr	9.2%	9.0%	0.2x
2020-01	19.3x	₹733 cr	9.2%	9.0%	0.2x
2019-12	20.5x	₹733 cr	9.2%	9.0%	0.2x
2019-11	22.0x	₹733 cr	9.2%	9.0%	0.2x
2019-10	20.9x	₹733 cr	9.2%	9.0%	0.2x
2019-09	20.2x	₹733 cr	9.2%	9.0%	0.2x
2019-08	15.6x	₹733 cr	9.2%	9.0%	0.2x
2019-07	25.6x	₹733 cr	9.2%	9.0%	0.2x
2019-06	24.9x	₹733 cr	9.2%	9.0%	0.2x
2019-05	27.1x	₹789 cr	9.5%	10.0%	0.2x
2019-04	30.4x	₹789 cr	9.5%	10.0%	0.2x
2019-03	26.4x	₹789 cr	9.5%	10.0%	0.2x
2019-02	27.1x	₹789 cr	9.5%	10.0%	0.2x
2019-01	29.5x	₹789 cr	9.5%	10.0%	0.2x

Methodology and data notes